Prediction of Non-motor Symptoms in Fully Ambulatory MS Patients Using Vocal Biomarkers
NCT ID: NCT05561621
Last Updated: 2023-06-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
70 participants
OBSERVATIONAL
2022-07-15
2022-12-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multiparametric Assessment to Investigate Prognostic Factors for Disease Evolution a nd Evolutionary Patterns of Cognitive Status in RRMS
NCT05510817
A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment
NCT00702065
A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis
NCT01737372
The Use of Technology to Improve MS Clinical Trials and Patient Care
NCT02454907
Implementation of a Novel Functional Eye-Tracking Biomarker for Multiple Sclerosis
NCT05277740
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with relapsing MS
Voice analysis
Voice analysis
Healthy controls
Voice analysis
Voice analysis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Voice analysis
Voice analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age over 18
* EDSS \< 4.0
* Capability of written informed consent
Exclusion Criteria
* Relapse or Steroids per os/intra venous \< 4 weeks prior to examination
* KM enhancing lesion in MRI \< 4 weeks prior to examination
* Other previous disease affecting the speech
* Pregnant patients
* Mental disability and not able to understand the protocol and study tasks in german languagePatients with greater physical and cognitive disability or history of major depressive disorder and suicide attempt/suicidal thoughts
* Patients with sleep disorders and comorbidities associated with extreme fatigue (e.g., fibromyalgia)
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Audeering GMBH
INDUSTRY
Biogen
INDUSTRY
Insel Gruppe AG, University Hospital Bern
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Helly Hammer
Role: PRINCIPAL_INVESTIGATOR
Inselspital, University Hospital Bern
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Inselspital University Hospital Bern
Bern, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DLF5177
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.